<unk>  is a PCSK9 (proprotein convertase subtilisin kexin type9) inhibitor antibody that is FDA approved for the treatment of Primary Hyperlipidemia, Homozygous Familial Hypercholesterolemia, Heterozygous Familial Hypercholesterolemia, or Clinical atherosclerotic cardiovascular disease (CVD)..   Common adverse reactions include Nasopharyngitis, upper respiratory tract infection, Influenza, back pain, and injection site reactions..
Evolocumab
Nebacumab
Ustekinumab
Alirocumab
Dupilumab
Burosumab
Durvalumab
Sarilumab